Get the Stockscreener App
16.77
4.53%
-0.795
After Hours:
16.80
0.03
+0.18%
Maplight Therapeutics Inc stock is traded at $16.77, with a volume of 240.56K.
It is down -4.53% in the last 24 hours and up +30.10% over the past month.
MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.
See More
Previous Close:
$17.57
Open:
$17.4
24h Volume:
240.56K
Relative Volume:
1.10
Market Cap:
$760.91M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-6.89%
1M Performance:
+30.10%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$15.58
$17.78
1-Week Range:
$15.58
$18.33
52-Week Range:
$12.24
$21.55
Maplight Therapeutics Inc Stock (MPLT) Company Profile
Name
Maplight Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Compare MPLT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MPLT
Maplight Therapeutics Inc
|
16.77 | 796.98M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-21-25 | Initiated | Jefferies | Buy |
| Nov-21-25 | Initiated | Leerink Partners | Outperform |
| Nov-21-25 | Initiated | Morgan Stanley | Overweight |
| Nov-21-25 | Initiated | Stifel | Buy |
Maplight Therapeutics Inc Stock (MPLT) Latest News
MapLight’s phase 2 Alzheimer’s psychosis trial marks a key milestone for MPLT investors - MSN
What is the current Price Target and Forecast for MapLight Therapeutics, Inc. (MPLT) - Zacks Investment Research
MapLight’s Phase 2 Alzheimer’s Psychosis Trial Marks a Key Milestone for MPLT Investors - TipRanks
MapLight Therapeutics Earnings Notes - Trefis
MapLight Therapeutics advances CNS drug pipeline - MSN
MapLight’s ML-004 Autism Extension Study: What Ongoing Safety Data Mean for Investors - TipRanks
MapLight Therapeutics, Inc.(NasdaqGS: MPLT) added to S&P TMI Index - marketscreener.com
Aktis Oncology files for US IPO as biotech listings rebound - whbl.com
MapLight2025 Funding Rounds & List of Investors - Tracxn
MapLight Therapeutics, Inc.(NasdaqGS: MPLT) added to Russell 2000 Growth Index - marketscreener.com
SandboxAQ and MapLight join forces on CNS - The Pharma Letter
6 Biotechs That Could Be Big Pharma’s Next M&A Target - BioSpace
SandboxAQ and MapLight Therapeutics Partner on Novel CNS Therapies - HPCwire
SandboxAQ and MapLight form $200 million CNS drug discovery alliance By Investing.com - Investing.com Nigeria
SandboxAQ and MapLight form $200 million CNS drug discovery alliance - Investing.com
MapLight links up with SandboxAQ to pursue AI-discovered CNS treatments - Axios
SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies - The Manila Times
Sandboxaq And Maplight Therapeutics Announce Collaboration To Discover And Develop Novel CNS Therapies - TradingView — Track All Markets
MapLight Therapeutics to join Russell 3000, Russell 2000 and Russell Microcap indexes - MSN
Potential Bristol Myers rival MapLight seeks $250M in U.S. IPO - MSN
MapLight Therapeutics completes IPO and raises $296.5M - MSN
Analysts Offer Insights on Healthcare Companies: MapLight Therapeutics, Inc. (MPLT) and Halozyme (HALO) - The Globe and Mail
Maplight Therapeutics (MPLT) Stock Trends and Sentiment 2025 - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Adversity is less terrifying than hope: MapLight Therapeutics Inc (MPLT) - setenews.com
MapLight Therapeutics Advances CNS Drug Pipeline - TipRanks
Florida key to BMS slip in ADP? Acadia sails ahead - BioWorld MedTech
Maplight Therapeutics (MPLT) Earnings Date and Reports 2026 - MarketBeat
Maplight Therapeutics reports third quarter financial results - marketscreener.com
MapLight Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - marketscreener.com
MapLight Therapeutics Completes IPO and Raises $296.5M - TipRanks
MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress - The Manila Times
MapLight Therapeutics, Inc. SEC 10-Q Report - TradingView
MPLT: Clinical pipeline advances and robust IPO funding position operations through 2027 - TradingView — Track All Markets
Positive Outlook on MapLight Therapeutics Amid ADEPT-2 Study Continuation and Upcoming Catalysts - TipRanks
MapLight stock rises as Jefferies reiterates Buy rating on schizophrenia drug By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
MapLight stock rises as Jefferies reiterates Buy rating on schizophrenia drug - Investing.com Canada
Bristol Myers (BMY) Advances in Alzheimer's Study Facing Trial C - GuruFocus
Marvell Posts Strong Q3 Earnings, Joins American Eagle, Microchip Technology, Box And Other Big Stocks Moving Higher On Wednesday - Benzinga
SETIA VISHWAS Insider Trades - Nasdaq
MapLight Therapeutics (MPLT) Stock Analysis Report | Financials & Insights - Benzinga
MPLT Interactive Stock Chart | MapLight Therapeutics, Inc. Stock - Yahoo! Finance Canada
MapLight Therapeutics, Inc. (MPLT) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
MapLight Therapeutics Closes Successful IPO and Private Placement - MSN
FOFF ERIN PENNOCK Insider Trades - Nasdaq
KROEGER CHRISTOPHER A Insider Trades - Nasdaq
MapLight Therapeutics stock rating reiterated at Overweight by Morgan Stanley - Investing.com Canada
MapLight Therapeutics initiated with a Buy at Stifel - MSN
Maplight Therapeutics Inc Stock (MPLT) Financials Data
There is no financial data for Maplight Therapeutics Inc (MPLT). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):